Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00023660 · ClinicalTrials.gov registry record · Phase 1
Radiation Therapy Plus Celecoxib, Fluorouracil, and Cisplatin in Patients With Locally Advanced Cervical Cancer
A Phase 1 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
NCT00023660 is a Phase 1 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 84 participants.
The verdict
NCT00023660, a Phase 1 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving radiation therapy in different ways and combining it with chemotherapy may kill more tumor cells. Celecoxib may slow the growth of cervical cancer by stopping blood flow to the tumor. PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy plus celecoxib, fluorouracil, and cisplatin in treating patients who have locally advanced cervical cancer.
Interventions
- DRUG cisplatin
- DRUG fluorouracil
- RADIATION radiation therapy
- RADIATION brachytherapy
- DRUG celecoxib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2001-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00023660
The ClinicalTrials.gov registry entry for NCT00023660 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00023660 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00023660 about?
NCT00023660 is a clinical study titled "Radiation Therapy Plus Celecoxib, Fluorouracil, and Cisplatin in Patients With Locally Advanced Cervical Cancer". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving radiation therapy in different ways and combining it with chemotherapy may kill more tumor cells. Celecoxib ...
What is the current status of trial NCT00023660?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2001-08.
What interventions are being tested in trial NCT00023660?
The interventions under investigation include: cisplatin (DRUG), fluorouracil (DRUG), radiation therapy (RADIATION), brachytherapy (RADIATION), celecoxib (DRUG).
Who is sponsoring clinical trial NCT00023660?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.